Achieving Recruitment Objectives In Dermatology Trial: Reducing Timeline And Cost

IQVIA Biotech was selected to help a U.S. biopharmaceutical company examine the safety and efficacy of its investigational therapy for the treatment of moderate-to-severe hidradenitis suppurativa (HS), a chronic skin condition that causes small, but painful lumps under the skin. This case study will highlight IQVIA Biotech’s unique strategies for site selection and centralized recruitment approach to drive enrollment. For more information, download the available case study.